Aldara for the Treatment of Large and/or Multiple sBCC

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

BCC is the most common form of skin cancer. Current treatment is often surgery but this can be limited by the number of lesions, their location the age of the patient or the potential cosmetic outcome. The purpose of this study is to evaluate the effectiveness of imiquimod, on a non surgical treatment, in subjects with multiple of large sBCCs.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: MEDA Pharma GmbH & Co. KG
• Treatments: Imiquimod

Criteria

Inclusion Criteria:

• One or more sBCC on torso, neck or face

• Total surface area <= 40 sq cm

Exclusion Criteria:

• Pregnancy or women who are breastfeeding

• Xeroderma pigmentosum, albinism, epidermodysplasia verruciformis, any genetic anomaly accompanied by skin tumors

• Metatypical, adnexal, or sclerodermiform carcinomas

• Current or other previous malignant skin tumor (epidermoid carcinoma, melanoma) in the region of the current lesion

• Known HIV positive serology

• Skin tumor that is already or highly likely to become metastatic

• Presence of a clinically significant anomaly or illness (immunological, cardiovascular, pulmonary, hematological, neurological, hepatic, renal, endocrine, gastrointestinal, collagenous)

• Previous organ transplant history